A NEW PERSPECTIVE ON BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP: POTENTIAL DIAGNOSTIC CRITERIA

Tetyana O. Pertseva, Lyudmyla I. Konopkina, Alina O. Babenko
DNIPROPETROVSK MEDICAL ACADEMY OF MINISTRY OF HEALTH OF UKRAINE, DNIPRO, UKRAINE

ABSTRACT
The aim: The aim of the research was to analyze the results of observation and examination of COPD patients in order to identify a group of individuals with potential asthma overlap.

Materials and methods: We have conducted a two-stage dynamic investigation of 43 COPD patients during 3–8 years. The patients were divided into two groups: group 1 counted 30 individuals who presented with at least one episode of reversible bronchial obstruction (RBO) during the observation; group 2 – 13 individuals who presented with nonreversible bronchial obstruction (nonRBO). At the first stage, we conducted a clinical observations analysis and studied lung function examination records; at the second stage, we calculated the markers of allergic inflammation.

Results: It was revealed that around 70% of COPD patients have occasional episodes of RBO. It was established that the level of blood eosinophils in these patients on the whole is rather low even in people with intermittent RBO, and the total IgE level appeared to be significantly higher in patients with intermittent RBO comparing to the level of this marker in patients who have nonRBO.

Conclusions: COPD patients with intermittent RBO and high level of total IgE level form a group with potential asthma overlap.

KEY WORDS: COPD, asthma, overlap, allergic airway inflammation, bronchial obstruction

INTRODUCTION
In the late 20th – early 21st century, a lot of academic research dealt with different issues related both to asthma [1, 2], and to chronic obstructive pulmonary disease (COPD) [3, 4, 5].

In 2014, after an extensive review of available academic literature, international experts first discussed in GINA and GOLD guidelines the possibility of asthma combination with COPD [6]. Later on, this combination was referred to as ACO, i.e. Asthma-COPD overlap [7]. To date, this topic is being actively discussed seeking to elaborate standards both for diagnosis, and for patient treatment. This includes updating diagnostic criteria for ACO, identifying diagnostic significance of the markers of pathologies combination at different stages of disease course, developing indications for medication administration at certain stages of disease course, specifying medication dose, etc. [8, 9, 10].

In our opinion, the combination of the two aforementioned diseases may progress in different ways: the first clinical case is a COPD overlap in the course of the existing asthma; the second case is an asthma overlap in the course of the existing COPD.

The first clinical case has been studied in more detail. It is shown that among patients with bronchial asthma, particularly among smokers, there are individuals with predominantly neutrophilic inflammation, rapid decrease in pulmonary ventilation or poorer response to bronchodilator or inhaled glucocorticosteroid (ICS) therapy [6, 7, 8]. It is also believed that the possibility of ACO formation in patients with asthma may be associated with risk factors for constantly progressing airflow limitation, such as childhood asthma, long-term asthma with no ICS intake, first asthma manifestations in adulthood, severe or treatment-resistant asthma [8, 9, 10]. According to the latest findings, ACO formation in patients with previously verified asthma may reach 29% [9].

The second clinical case is quite rarely discussed in academic literature. Yet, it has been determined that a significant number of patients with COPD may occasionally present with reversible bronchial obstruction (RBO) [10, 11], which is more typical of asthma. In COPD, it is mainly explained by bronchial hyperresponsiveness (one of its mechanisms is an expression of a CD38 marker, which catalyzes the formation in smooth muscle cells of cyclic ADP-ribose with further calcium mobilization from intracellular stores [12]) or insufficient or inadequate pharmaceutical treatment [13]. It is also found that, among COPD patients, certain individuals’ laboratory test results are more typical of asthma, which is particularly true for high sputum eosinophil count [11]. To date, the mechanisms of connection between clinico-functional and laboratory findings in ACO haven’t been clearly identified; the criteria for unified clinical diagnosis verification have not been determined, either. In view of this, our research focused on this very issue.
THE AIM
The aim of the research was to analyze the results of long-term observation and examination of patients with previously verified COPD in order to identify a group of individuals with possible asthma overlap as well as to determine the markers of COPD and asthma combination.

MATERIALS AND METHODS
The research was carried out in two stages. At the first stage, we analyzed conducted a clinical observations analysis and studied the records of dynamic lung function examination of 43 COPD patients in stable condition only. The observation period made 3–8 years, during which 240 clinic visits were performed (an average number of visits per each patient was 6.5 (2.2)). At all visits, the severity of ventilatory failure was determined in all patients via spirometry with the calculation of the degree of airway obstruction reversibility was determined via bronchodilator testing (400 mcg salbutamol delivered by a spacer device). Based on post-bronchodilator FEV1, the patients were referred to groups GOLD II and III.

At the second stage of the research, allergic status markers were identified for all the aforementioned patients: we performed a complete blood count to calculate eosinophil level in absolute value (µL) and measured the total serum IgE (IU/ml) using the enzyme-linked immunosorbent assay.

The COPD diagnoses were formulated according to the Order of the Ministry of Healthcare of Ukraine № 555 from 27 June 2013. All patients received adequate background therapy depending on the clinical group of the disease and according to international and national guidelines depending on the severity of disease course (long-acting bronchodilators with/without ICS as a routine therapy and short-acting β2-agonist salbutamol as required).

All patients gave a written consent for retrospective clinical observations analysis and laboratory investigations.

The study was conducted according to Helsinki declaration with the permission of the Bioethical commission Dnipropetrovsk medical academy of the Ministry of Health of Ukraine.

Statistical data processing were performed using the STATISTICA 6.1 software (“StatSoftInc”, serial number AGAR909E-415822FA). Quantitative data were analyzed after the arithmetic mean and standard deviation at normal markers distribution and after the median and interquartile range [25%;75%] (in M (SD)) at non-normal markers distribution. The type of quantitative data distribution was determined after the Shapiro-Wilk (W) and Kolmogorov-Smirnov (D) criteria; the data were clinically significant at p > 0.05. Qualitative characteristics of the markers (elevated/normal) were presented as a number of patients (n) having those markers, and as relative frequencies expressed as a percentage (%). To compare two independent groups of markers, we used the Mann-Whitney U-test (U) in case of non-normal data distribution. The probability of differences in the relative indices (of data distribution) was identified via Fisher’s exact test; the differences between the groups at p < 0.05 were considered significant.

RESULTS AND DISCUSSION
The clinical observations analysis at the end of the first stage of the research showed that male patients were a majority (35 (81.4%)); an average age at the first clinic visit was 62.0 (7.15); body mass index (BMI) was 27.3 (4.3); all patients had a history of smoking in the past or upon initial examination (a pack-year ratio – 27.8 (4.9)); disease duration – 15.7 (3.9) years.

We noticed that at the initial stages of COPD development, the patients’ diagnosis was clear: the patients complained of first clinical signs of the disease at the age > 40 (at first, they presented primarily with a cough; further on, they developed a shortness of breath, increased cough, sputum containing mucus and pus); the presence of a post-bronchodilator FEV1/FVC < 0.70 was confirmed spirometrically.

At patients observation stages (during each subsequent clinic visit), we controlled both clinical, and spirometrical markers. It was established that a certain part of the patients had developed clinical symptoms variability – at different visits, shortness of breath and cough had different severity, despite the fact that the patients received regular and full-fledged medication therapy. Besides, the same patients appeared to have variable spirometrical markers. At the same time, we encountered with the patients whose clinical symptoms and functional performance remained stable throughout the long-term observation. Following the above mentioned, all examined patients were divided into two groups: group 1 counted 30 (69.8%) individuals who presented with at least one episode of RBO during the long-term observation (post-bronchodilator FEV1 increased by > 12% and > 200 ml comparing to baseline characteristics; FEV1 increase fluctuation had a wide range of 12.2 to 69% and of 230 to 910 ml); group 2 counted 13 (30.2%) individuals who presented with nonreversible bronchial obstruction (nonRBO) throughout the whole observation period. The average age in group 1 didn’t differ from that in group 2 (60.6 (7.18) and 65.2 (6.19) years, respectively) (two-tailed Student’s t-test: t = 1.83; the number of degrees of freedom is 41; p = 0.074); body mass index (BMI) was similar in both groups (27.5 (4.5) and 26.8 (3.8) kg/m2, respectively) (two-tailed Student’s t-test: t = 0.46; the number of degrees of freedom is 41; p = 0.647).

Thus, it was demonstrated that around 2/3 of patients with previously verified COPD have occasional episodes of RBO. Obviously, RBO may be associated with a number of factors. However, in order to exclude the possibility of asthma overlap in these patients, the following stage of the research was performed.

At the second stage, it was shown that the identified groups of patients had somewhat different number of individuals with elevated and normal blood eosinophils and/or total IgE (Table 1).

It is noteworthy that, if group 1 presented with elevated eosinophil count a bit more frequently than group 2 (although statistically inaccurate), elevated total IgE was detected in group 1 in 40% of cases, while in group 2 it was not detected in any case. Consequently, the eosinophil marker demon-
strated a quite low sensitivity as to the identification of the patients’ allergic state, since in many of those, at high total IgE, blood eosinophils didn’t exceed the reference values.

The absolute values of allergic state markers in the groups of the examined patients are provided in Fig 1 and 2.

It was discovered that blood eosinophils in COPD patients in the stable disease phase are in general quite low, and in the majority of individuals (86.1%) they do not exceed 0.4 µL. Besides, this marker in patients with COPD who have intermittent RBO (group 1) doesn’t differ from that in patients who have nonRBO (group 2) (р=0.827).

Total IgE in COPD patients who have intermittent RBO appeared to be significantly higher than that in patients who have nonRBO (р=0.008).

Our findings match the results of other researches, which show that peripheral blood eosinophil count in COPD patients doesn’t correlate either with bronchial hyperresponsiveness rate, or with the number of disease exacerbations, and is in general quite low [13, 14, 15].

Our findings don’t contradict the recent study, which also demonstrates that increased total IgE (44%) is pretty common for COPD patients. The latter may witness to the lower airway allergic inflammation in certain COPD patients even without any clinical manifestations of atopy, and therefore, be a marker of ACO [15].

Therefore, our research enabled us to identify a group of COPD patients, whose diagnosis at the initial stages of the disease was clear and characterized by the following typical signs: long-term tobacco smoking, first clinical manifestations of the disease at the age > 40, gradually increasing shortness of breath and cough with sputum containing mucus and pus, spirometrically confirmed the presence of a post-bronchodilator FEV1/FVC < 0.70. However, with the diseases development, these patients presented with the signs of a different illness – asthma: intermittent RBO, elevated total IgE and sometimes blood eosinophilia. Keeping in mind a stage-like nature of diseases overlap, we recommend referring to such clinical cases as CAO (i.e. COPD-Asthma overlap) instead of ACO. The formation of CAO may require patient treatment revision and management; particularly, treatment regimen should include high doses of ICS if patients have not taken any before.

**CONCLUSIONS**

1. COPD patients require compulsory long-term dynamic observation not only to control clinical and functional performance and medication therapy management (as appropriate), but also to exclude possible asthma overlap with further CAO development and, consequently, to manage treatment strategy.
2. Blood eosinophilia determination in COPD patients is not recommended for identifying the possibility of CAO formation due to a low diagnostic sensitivity of this marker.

3. Both dynamic control of RBO and total serum IgE determination (at least occasional) are recommended for verifying CAO formation in the course of COPD.

4. In case of CAO formation, patient follow-up should lean on diagnostic and treatment standards not only for COPD, but also for bronchial asthma.

REFERENCES


ORCID and contributionship:
Tetyana O. Pertseva: 0000-0001-6998-4974 A,D,E,F
Lyudmyla I. Konopkina: 0000-0002-2238-6501 A,B,C,D,E
Alina O. Babenko: 0000-0002-4344-8871 B,C,D

Conflicts of interest:
Authors declare no conflict of interest.

CORRESPONDING AUTHOR
Alina. O. Babenko
Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine
13 Batumska st., 49000 Dnipro, Ukraine
tel: +380933078588
e-mail: alinababenko2406@gmail.com

Received: 29.08.2019
Accepted: 27.04.2020